Cargando…
Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study
OBJECTIVES: As early prediction of severe illness and death for patients with coronavirus disease 2019 (COVID-19) is important, we aim to explore the clinical value of laboratory indicators in evaluating the progression and prognosis of patients with COVID-19. DESIGN: Retrospective cohort study. SET...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488281/ https://www.ncbi.nlm.nih.gov/pubmed/34598979 http://dx.doi.org/10.1136/bmjopen-2020-043790 |
_version_ | 1784578129286660096 |
---|---|
author | Wang, Qian Cheng, Jie Shang, Jian Wang, Ying Wan, Jing Yan, You-qin Liu, Wen-bin Zhang, Hai-Ping Wang, Jian-ping Wang, Xiao-yue Li, Zi-ang Lin, Jun |
author_facet | Wang, Qian Cheng, Jie Shang, Jian Wang, Ying Wan, Jing Yan, You-qin Liu, Wen-bin Zhang, Hai-Ping Wang, Jian-ping Wang, Xiao-yue Li, Zi-ang Lin, Jun |
author_sort | Wang, Qian |
collection | PubMed |
description | OBJECTIVES: As early prediction of severe illness and death for patients with coronavirus disease 2019 (COVID-19) is important, we aim to explore the clinical value of laboratory indicators in evaluating the progression and prognosis of patients with COVID-19. DESIGN: Retrospective cohort study. SETTING: Hospital-based study in China. PARTICIPANTS: Adult patients with COVID-19 from December 15, 2019 to March 15, 2020. END POINT: Disease severity and mortality. METHODS: Clinical data of 638 patients with COVID-19 were collected and compared between severe and non-severe groups. The predictive ability of laboratory indicators in disease progression and prognosis of COVID-19 was analysed using the receiver operating characteristic curve. The survival differences of COVID-19 patients with different levels of laboratory indicators were analysed utilising Kaplan-Meier analysis. RESULTS: 29.8% (190/638) of patients with COVID-19 progressed to severe. Compared with patients with no adverse events, C reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR) and D-dimer were significantly higher in severe patients with adverse events, such as acute myocardial injury, respiratory failure, acute kidney injury, mechanical ventilation, intensive care unit admission, multiple organ dysfunction syndromes and death (all p<0.05). The multivariate logistic analysis suggested that CRP, NLR and D-dimer were independent risk factors for the disease progression of COVID-19 (all p<0.05). The model combining all of them owned the highest area under the receiver operating characteristic curve (AUC) predicting disease progression and death of COVID-19, with AUC of 0.894 (95% CI 0.857 to 0.931) and 0.918 (95% CI 0.873 to 0.962), respectively. Survival analysis suggested that the patients with a high level of CRP, NLR or D-dimer performed shorter overall survival time (all p<0.05). CONCLUSIONS: The combination of CRP, NLR and D-dimer could be an effective predictor for the aggravation and death in patients with COVID-19. The abnormal expression of these indicators might suggest a strong inflammatory response and multiple adverse events in patients with severe COVID-19. |
format | Online Article Text |
id | pubmed-8488281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-84882812021-10-04 Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study Wang, Qian Cheng, Jie Shang, Jian Wang, Ying Wan, Jing Yan, You-qin Liu, Wen-bin Zhang, Hai-Ping Wang, Jian-ping Wang, Xiao-yue Li, Zi-ang Lin, Jun BMJ Open Infectious Diseases OBJECTIVES: As early prediction of severe illness and death for patients with coronavirus disease 2019 (COVID-19) is important, we aim to explore the clinical value of laboratory indicators in evaluating the progression and prognosis of patients with COVID-19. DESIGN: Retrospective cohort study. SETTING: Hospital-based study in China. PARTICIPANTS: Adult patients with COVID-19 from December 15, 2019 to March 15, 2020. END POINT: Disease severity and mortality. METHODS: Clinical data of 638 patients with COVID-19 were collected and compared between severe and non-severe groups. The predictive ability of laboratory indicators in disease progression and prognosis of COVID-19 was analysed using the receiver operating characteristic curve. The survival differences of COVID-19 patients with different levels of laboratory indicators were analysed utilising Kaplan-Meier analysis. RESULTS: 29.8% (190/638) of patients with COVID-19 progressed to severe. Compared with patients with no adverse events, C reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR) and D-dimer were significantly higher in severe patients with adverse events, such as acute myocardial injury, respiratory failure, acute kidney injury, mechanical ventilation, intensive care unit admission, multiple organ dysfunction syndromes and death (all p<0.05). The multivariate logistic analysis suggested that CRP, NLR and D-dimer were independent risk factors for the disease progression of COVID-19 (all p<0.05). The model combining all of them owned the highest area under the receiver operating characteristic curve (AUC) predicting disease progression and death of COVID-19, with AUC of 0.894 (95% CI 0.857 to 0.931) and 0.918 (95% CI 0.873 to 0.962), respectively. Survival analysis suggested that the patients with a high level of CRP, NLR or D-dimer performed shorter overall survival time (all p<0.05). CONCLUSIONS: The combination of CRP, NLR and D-dimer could be an effective predictor for the aggravation and death in patients with COVID-19. The abnormal expression of these indicators might suggest a strong inflammatory response and multiple adverse events in patients with severe COVID-19. BMJ Publishing Group 2021-10-01 /pmc/articles/PMC8488281/ /pubmed/34598979 http://dx.doi.org/10.1136/bmjopen-2020-043790 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Infectious Diseases Wang, Qian Cheng, Jie Shang, Jian Wang, Ying Wan, Jing Yan, You-qin Liu, Wen-bin Zhang, Hai-Ping Wang, Jian-ping Wang, Xiao-yue Li, Zi-ang Lin, Jun Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study |
title | Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study |
title_full | Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study |
title_fullStr | Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study |
title_full_unstemmed | Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study |
title_short | Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study |
title_sort | clinical value of laboratory indicators for predicting disease progression and death in patients with covid-19: a retrospective cohort study |
topic | Infectious Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488281/ https://www.ncbi.nlm.nih.gov/pubmed/34598979 http://dx.doi.org/10.1136/bmjopen-2020-043790 |
work_keys_str_mv | AT wangqian clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT chengjie clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT shangjian clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT wangying clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT wanjing clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT yanyouqin clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT liuwenbin clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT zhanghaiping clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT wangjianping clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT wangxiaoyue clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT liziang clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy AT linjun clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy |